Introduction {#s1}
============

Chronic obstructive pulmonary disease (COPD) is a lung disease characterised by chronic airflow obstruction that interferes with normal breathing and is not fully reversible \[[@C1]\]. The prevalence in Sweden is approximately 10% in the adult population \[[@C2]\] which is in agreement with global reports \[[@C3]\]. There is presently no cure for COPD and it is the only endemic disease in Sweden for which mortality is increasing \[[@C4]\]. The number of patients with COPD is also increasing worldwide and it is the third most common cause of death globally \[[@C5]\]; thus its impact both from an epidemiological and a health economic standpoint is considerable. Although it is a disease of the small airways and the lung, patients with COPD have a significant comorbidity with many symptoms and physical and emotional dysfunctions \[[@C6]\].

Because breathing and swallowing share neuroanatomical substrates and pathways, there must be a precise coordination between them to protect the airway. Despite the essentiality of this coordination for safe and efficient swallowing, there is still a lack of information about how it is impacted by disease in general and by COPD in particular \[[@C7]\]. Swallowing symptoms, or oropharyngeal dysphagia, are clinical symptoms defined as difficulty in effectively moving food and liquid from the mouth to the oesophagus \[[@C8]\]. In this study, dysphagia will refer to oropharyngeal dysphagia unless otherwise indicated. The consequences of dysphagia broadly affect respiratory safety (aspiration) and swallowing efficiency (adequacy of nutrition and hydration by mouth) \[[@C9]\]. The true prevalence is difficult to determine as research typically categorise prevalence according to the concomitant medical disorder (*e.g.* head/neck cancer, stroke, Parkinson\'s disease). Determining the true prevalence also depends on the diagnostic instrument used. Despite these limitations it is recognised that dysphagia is a highly prevalent clinical condition affecting 29%--64% of all stroke patients \[[@C10]\] and up to 81% of people with Parkinson\'s disease \[[@C11]\]. Some studies have shown that the prevalence of dysphagia among independently living older people is 16% among the 70--79-year olds and 33% among octogenarians \[[@C12]\]. Dysphagia has also been identified as a risk factor for acute exacerbations of COPD \[[@C13]--[@C15]\]. As aspiration has been reported in patients with COPD, K[obayashi]{.smallcaps} *et al*. \[[@C16]\] stress the importance of early and accurate identification of those patients with COPD who require a more in-depth assessment of swallowing function.

The diagnosis of dysphagia can be based on functional health status questionnaires, clinical assessments, or instrumental evaluations \[[@C17]\]. The implementation of swallowing screening protocols has reduced pneumonia incidence in patients with stroke \[[@C18]\]. In their systematic review on screening tools for dysphagia, however, E[tges]{.smallcaps} *et al*. \[[@C19]\] found that the protocols were heterogeneous and developed for patients with different underlying pathologies. A first attempt to develop a screening protocol specific for the COPD population was made by R[egan]{.smallcaps} *et al*. \[[@C20]\]. In their pilot study in 2017, they investigated the Eating Assessment Tool (EAT)-10 \[[@C21]\] as a protocol to identify adults with stable COPD who aspirate during swallowing.

In a number of studies, the prevalence of swallowing dysfunction has been reported to be higher in patients with stable COPD than in the general population \[[@C17], [@C22]--[@C24]\]. Studies on swallowing dynamics and pulmonary function have concluded that an integrated breathing and swallowing pattern is often suboptimal in patients with COPD, thereby affecting some patients\' ability to swallow and to swallow safely \[[@C25]\]. L[angmore]{.smallcaps} *et al*. \[[@C26]\] showed that COPD was the strongest independent comorbidity predictor (OR 2.49) for aspiration pneumonia in patients in nursing homes. In a recent systematic review on swallowing function and chronic respiratory disease \[[@C17]\], the outcome data indicate that chronic respiratory diseases increase the prevalence of oropharyngeal dysphagia in patients. Oesophageal dysphagia in the form of gastro-oesophageal reflux has also been reported as more common in patients with COPD \[[@C27]\] and associated with more frequent exacerbations; however, the exact prevalence of either oropharyngeal or oesophageal dysphagia in patients with COPD is not fully understood nor is the disease\'s impact on swallowing function and the patient\'s perception of this. Like COPD, the impact of dysphagia is considerable both from an epidemiological and an individual patient perspective; it can lead to aspiration, malnutrition, and a heavy burden on healthcare resources \[[@C28]\].

The aim of this study was to investigate the prevalence of subjective (*i.e.* self-reported) swallowing symptoms in a large cohort of patients with stable COPD and identify potential related risk factors.

Materials and methods {#s2}
=====================

Participants {#s2a}
------------

The study data were derived from the Swedish Tools Identifying Exacerbations in COPD-study (TIE-study) which is a prospective, cross-sectional, and multicentre study in primary and secondary care \[[@C29]\]. Patients (n=571; 59% female) from primary and secondary care in three Swedish counties were recruited between September 2014 and September 2016. Inclusion criteria were a spirometry-verified COPD diagnosis, a post-bronchodilator ratio of the forced expiratory volume in 1 s (FEV~1~)/vital capacity (VC) or forced vital capacity (FVC)\<0.70; age≥40 years; and the ability to independently fill in the questionnaire and participate in the tests of physical capacity. Patients with severe comorbidities (*e.g.* dementia, metastasised cancer, severe cardiac insufficiency or severe sequelae from stroke) were excluded. None was in an acute phase of the disease. All patients were ambulatory, lived at home (not in a nursing facility) and were taking their full nutrition (liquid and solid) by mouth.

Procedure {#s2b}
---------

Data were collected in a clinical environment by research nurses and members of the TIE-study group. Spirometries were performed by the trained research nurses. The following investigations were of interest for this substudy: questionnaire, spirometry test and test of physical capacity

Questionnaire {#s2c}
-------------

A questionnaire comprising 61 questions separated by theme was designed to collect information on comorbidity, smoking history, number of COPD exacerbations and exacerbation-related hospitalisations during the previous year. It included the modified Medical Research Council (mMRC), and COPD Assessment Test (CAT), which are two self-rating tools to evaluate the impact of dyspnoea (mMRC) and health-related quality of life (CAT) in patients with COPD \[[@C30], [@C31]\]. Following the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines \[[@C32]\] we defined patients with COPD as being more symptomatic if they had an mMRC score ≥2 or a CAT score ≥10.

Swallow-specific data were collected through three questions: (1) I cough when I eat; (2) Food/drink goes down the wrong way when I eat; and (3) Food sticks in my throat when I eat. At the time, there was no validated dysphagia questionnaire available in Sweden. These three questions are some of the strongest clinical signs for identifying oropharyngeal dysphagia \[[@C8]\], they have been used in a previous study on COPD and swallowing \[[@C22]\] and are also used in several validated dysphagia screening protocols \[[@C21]\]. Thus, the patients in our study were dichotomised into either a dysphagia or nondysphagia group. Anyone who answered "yes" to any of the questions was accepted into the dysphagia group, since the aim was to study prevalence and not the degree of possible swallowing symptoms.

Spirometry {#s2d}
----------

Spirometry was performed using either a Spiro Perfect Spirometer (Welch Allyn, Skaneateles Falls, NY, USA) or a Jaeger Master Screen PFT (Erich Jaeger, GmbH, Würtzburg, Germany). A post-bronchodilator ratio (15 min after administration of 400 µg salbutamol) of FEV~1~/best of FVC and VC \<0.7 was used to define COPD. Swedish reference values \[[@C33]\] were applied for the FEV~1.~

Test of physical capacity {#s2e}
-------------------------

Physical capacity (endurance and leg muscle strength) was measured by the time to walk 30 metres at maximum speed \[[@C34]\].

Body mass index {#s2f}
---------------

Height and weight were measured at the visit. Body mass index (BMI) was calculated using the formula: weight (kg)/height (m^2^).

Exacerbation {#s2g}
------------

An exacerbation was defined as unscheduled visits and/or course of oral steroids and/or a course of antibiotics due to COPD deterioration. Frequent exacerbations were defined as having at least two exacerbations or at least one hospital admittance due to a COPD exacerbation during the year prior to study inclusion.

The GOLD classification {#s2h}
-----------------------

The goals of COPD assessment are to determine the severity of airflow limitation, its impact on patient\'s health status and risk of future events such as exacerbations, hospital admissions and death. This is done in two ways: spirometry is performed to assess and classify the airflow limitation (stage 1--4) and secondly an assessment of either dyspnoea using mMRC or health status using CAT together with their history of exacerbations during the last year. This categorises patients into group A, B, C or D \[[@C32]\]. In this study, symptom assessment by CAT was used for risk stratification.

Ethical approval {#s2i}
----------------

The Regional Review Board in Uppsala, Sweden (Dnr 2013/358) approved the study on April 28, 2014. All subjects gave written informed consent.

Statistical analysis {#s2j}
--------------------

Descriptive and comparative statistical calculations were made through SPSS statistics, version 24 (IBM, Armonk, NY, USA). Demographic data are reported as means, median, standard deviation and range. Group-wise differences for numerical values were tested with an unpaired t-test or Mann--Whitney U-test, whereas categorical values were compared using the Chi-squared test. A p-value \<0.05 was regarded as significant.

Results {#s3}
=======

As can be seen in [table 1](#TB1){ref-type="table"}, 33% (n=186) of the 571 patients reported at least one of the three swallowing symptoms. Participants presented with mild (n=57), moderate (n=314), severe (n=155) and very severe (n=45) COPD. The most common comorbidity in this study was chronic bronchitis, followed by asthma and heart disease ([table 1](#TB1){ref-type="table"}). No significant relation was found between swallowing symptoms and sex, age, exacerbations or comorbidities (p\>0.05).

###### 

Characteristics of the study population

  **Characteristics**                        **Total**   **Subjective swallowing symptoms**   **No swallowing symptoms**
  ----------------------------------------- ----------- ------------------------------------ ----------------------------
  **Subjects**                                  571                  186 (33%)                        385 (67%)
  **Sex**                                                                                    
   Female                                       335                  112 (33%)                        223 (67%)
   Male                                         236                   74 (31%)                        162 (69%)
  **Age years**                              68.6±7.6                 68.9±7.8                         68.4±7.6
  **GOLD spirometric stage**                                                                 
   Stage 1, FEV~1~ ≥80% predicted               57                    22 (39%)                         35 (61%)
   Stage 2, FEV~1~ 50--\<80% predicted          314                   96 (31%)                        218 (69%)
   Stage 3, FEV~1~ 30--\<50% predicted          155                   56 (36%)                         99 (64%)
   Stage 4, FEV~1~ \<30% predicted              45                    12 (27%)                         33 (73%)
  **GOLD 2017**                                                                              
   Group A                                      188                   40 (21%)                        148 (79%)
   Group B                                      244                   98 (40%)                        146 (60%)
   Group C                                      29                    3 (10%)                          26 (90%)
   Group D                                      110                   45 (41%)                         65 (59%)
  **Spirometry**                                                                             
   FEV~1~ % predicted                        56.6±17.8               57.0±18.3                        56.3±17.6
   FEV~1~ L                                  2.9±0.91                2.81±0.85                         3.0±0.93
  **Smoking status**                                                                         
   Current smoker                               165                   42 (26%)                        123 (74%)
   Former smoker                                395                  140 (35%)                        255 (65%)
   Never-smoker                                  9                    2 (22%)                          7 (78%)
  **Weight**                                                                                 
   Stable                                       377                  108 (29%)                        269 (71%)
   Weight gain                                  111                   43 (39%)                         68 (61%)
   Weight loss                                  80                    34 (42%)                         46 (58%)
  **BMI kg·m^−2^**                           26.8±5.1                 28.1±5.6                         26.2±4.6
   Underweight, BMI \<18.5 kg·m^−2^             25                    6 (24%)                          19 (76%)
   Normal weight, BMI 18.5--24.9 kg·m^−2^       199                   54 (27%)                        145 (73%)
   Overweight, BMI 25--29.9 kg·m^−2^            207                   61 (29%)                        146 (71%)
   Obese, BMI ≥30 kg·m^−2^                      137                   65 (47%)                         72 (53%)
  **Comorbidities**                                                                          
   Stroke/TIA                                   50                    20 (40%)                         30 (60%)
   Obstructive sleep apnoea                     60                    27 (45%)                         33 (55%)
   Rheumatoid arthritis                         65                    24 (37%)                         41 (63%)
   Asthma                                       189                   72 (38%)                        117 (62%)
   Chronic bronchitis                           193                   80 (41%)                        113 (59%)
   Heart disease                                114                   49 (43%)                         65 (57%)
  **Symptom burden**                                                                         
   Dyspnoea, mMRC score ≥2                      252                  116 (46%)                        136 (54%)
   Health-related QoL, CAT score ≥10            354                  143 (40%)                        210 (60%)
  **Exacerbations**                                                                          
   ≤1 during previous year                      432                  138 (32%)                        294 (68%)
   \>1 or hospital admission                    139                   48 (35%)                         91 (65%)

Data are presented as mean±[sd]{.smallcaps} unless otherwise stated. GOLD: Global initiative for Obstructive Lung Disease; FEV~1~: forced expiratory volume in 1 s; BMI: body mass index;

TIA: transient ischaemic attack; mMRC: modified Medical Research Council; QoL: quality of life; CAT: COPD Assessment Test.

Subjective swallowing symptoms {#s3a}
------------------------------

Of the 571 patients, 14% reported coughing when eating, 22% reported that "food/drink goes down the wrong way when I eat" and 23% reported that "food sticks in my throat when I eat". Two of the swallowing symptoms was reported by 53% (n=99) of the patients and 26% (n=49) said "yes" to all three. Of these 49 patients who experienced all three swallowing symptoms, 74% (n=35) were found in the symptomatic dyspnoea group (mMRC ≥2), 86% (n=42) in the group with poorer health-related quality of life (CAT ≥10) and finally 37% (n=18) in the group with frequent exacerbations. Participants with swallowing symptoms were more often in GOLD group B and D than those without swallowing symptoms at 40% and 41% compared with 21% and 10% respectively, p\<0.001 ([figure 1](#F1){ref-type="fig"}).

![Participants with and without subjective swallowing symptoms according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 classification.](00081-2019.01){#F1}

A significant relation was found between swallowing symptoms and dyspnoea, assessed as mMRC≥2 compared with \<2 (46%, n=116 *versus* 22%, n=70, p\<0.001) and health-related quality of life, assessed as CAT ≥10 (40%, n=143 *versus* 19%, n=42, p\<0.001). Hence the risk of experiencing swallowing symptoms was more than doubled in the groups that were more symptomatic ([figure 2](#F2){ref-type="fig"}).

![Participants with and without subjective swallowing problems according to modified Medical Research Council (mMRC) and COPD Assessment Test (CAT) classification. Darker shading in the bar graph indicates swallowing problems.](00081-2019.02){#F2}

A similar percentage of participants experienced swallowing symptoms in the different stages of airflow limitation (GOLD 1--4): 39% in stage 1, 31% in stage 2, 36% in stage 3 and 27% in stage 4, meaning no significant difference was found (p=0.28). Subjects with swallowing symptoms needed a longer time to walk 30 m (median (interquartile range)) than subjects without dysphagia: 19.1 s (16.9, 23) *versus* 18.4 s (16.3, 21.5), p=0.02.

Discussion {#s4}
==========

The primary finding of this study was that the prevalence of subjective swallowing symptoms was significantly higher in our COPD population (33%) than the 2.3--16% range reported in the general population \[[@C35]\] and the 16% reported among independently living older persons aged 70--79 years \[[@C36]\]. In their case-control study, C[vejic]{.smallcaps} *et al*. \[[@C13]\] found that the penetration/aspiration scores were higher in patients with COPD (3.3±0.7 *versus* 1.6±0.4) than in healthy controls (p=0.03). Further, penetration/aspiration was associated with higher respiratory rates (p=0.01) although none of the patients had subjective swallowing complaints. C[layton]{.smallcaps} *et al*. \[[@C37], [@C38]\] looked at laryngopharyngeal sensitivity in patients with stable COPD and compared the endoscopic evaluation of swallowing with a valid standardised clinical assessment of the same patient and found that patients with no subjective swallowing complaints showed evidence of pharyngeal compensation when compared with a control group. Possible explanations for this unawareness are polypharmacy and the simple fact that coughing is the most recognised sign of aspiration; it might therefore be difficult to distinguish a generic COPD cough from an aspiration cough.

The characteristics of oropharyngeal swallowing symptoms in patients with COPD are not yet defined. The most commonly reported symptom in this study was food lodging in the throat (*i.e.* bolus retention). This indicates residue in the oropharynx, valleculae, hypopharynx and/or pyriform sinuses. S[tein]{.smallcaps} *et al*. \[[@C24]\] found that patients with COPD have an increased risk of cricopharyngeal dysfunction, which often results in bolus retention in the pyriform sinuses. Since respiratory and limb muscle fatigue are commonly observed in this patient group \[[@C39]\], it is also possible that the oral and pharyngeal muscles are negatively affected secondary to a general deconditioning due to physical inactivity. This in turn may cause pharyngeal bolus retention.

Another common reason for bolus retention is xerostomia (dry mouth). Chronic xerostomia is a significant burden for many individuals, because it can affect chewing, swallowing, denture-wearing and general wellbeing \[[@C40]\]. Xerostomia is a common problem in patients with COPD due to mouth breathing and the use of inhaled bronchodilators and corticosteroids \[[@C20], [@C41]\]. In addition, polypharmacy significantly influences patients\' saliva.

Overall, 22% of the patients in our study reported that "food/drink goes down the wrong way when I eat" and 14% reported coughing when eating. The main sign of aspiration (*i.e.* food and drink going down the wrong way), is coughing and the main symptom for some patients with COPD is daily coughing \[[@C42]\] which means that it might be difficult for the patient to distinguish a COPD cough from an aspiration cough; hence a chronic cough could potentially mask an aspiration. Because breathing and swallowing share a common pathway, they must be precisely coordinated to protect the airway \[[@C7]\]. Changes in the ventilation pattern can compromise swallowing as C[vejic]{.smallcaps} *et al.* \[[@C13]\] also found when they studied the swallowing of 16 patients with COPD using videofluoroscopy while monitoring respiration.

Like dysphagia, dyspnoea is a subjective experience. Our findings of a strong relationship between swallowing symptoms and dyspnoea are perhaps not surprising, since swallowing can unmask or exacerbate dyspnoea. Swallowing requires the usual tidal breathing pattern to be changed to meet certain demands (*e.g.* higher pressures must be generated and expiration must cease momentarily). The current understanding of dyspnoea in relation to swallowing is that the modification of the breathing pattern necessary for swallowing can create breathing discomfort. In turn breathing discomfort can cause people to alter their swallowing behaviours \[[@C43]\]. A questionnaire-based survey on swallowing-related dyspnoea by H[oit]{.smallcaps} *et al*. \[[@C43]\], where 133 patients with COPD participated (mean age: 66.5 years) found that 74% experienced breathing discomfort during eating and drinking. However, no data regarding COPD severity or lung function were provided.

In a previous study, we found a clear negative correlation between lung function and dysphagia burden; the poorer the participants\' lung function, the more signs and symptoms of dysphagia \[[@C22]\]. However, in the current study there was no clear association between lung function and subjective swallowing symptoms, as a similar percentage of subjects experienced swallowing symptoms in the different stages of airflow limitation. Possible explanations for this discrepancy may be that in the previous study, the patients were older and more symptomatic, with the majority classified as GOLD stages 3 and 4 (74% *versus* 35%), which implies more cases of polypharmacy and comorbidity. Also, the first study screened dysphagia both subjectively and objectively.

In the revised recommendations of GOLD, spirometry has been removed from the risk assessment and is used only to grade the patient\'s airflow limitation from 1 to 4. The risk assessment into groups A to D are now based solely on the symptom burden and exacerbation history \[[@C32]\]. Interestingly there was a clear stratification within the group with swallowing symptoms, where groups B and D had a higher prevalence of swallowing symptoms than groups A or C (p\<0.001) ([figure 1](#F1){ref-type="fig"}).

Physical activity levels are frequently lower in the COPD population \[[@C44]\]. Walking distance is a predictor of exacerbations in patients with COPD \[[@C45]\]. During pulmonary rehabilitation, a 6-min walk test is typically performed. In this study a 30-m walk test was used and our data suggest a relationship between a longer time to walk 30 m and subjective swallowing symptoms.

Dysphagia is also a precipitating factor for malnutrition in COPD \[[@C46]\]. Interestingly, in this study there was no positive correlation between subjective swallowing problems and BMI. In fact, the mean BMI in both groups was in the overweight category. It is well established that patients with COPD have a decreased level of physical capacity, primarily due to breathlessness and therefore easily gain weight. Our data suggest that BMI is not a good variable for identifying dysphagia in patients with COPD.

Strengths and limitations {#s4a}
-------------------------

The strength of this study was that the study population was sampled from multiple centres, both primary and secondary care facilities. It included patients with different degrees of airflow obstruction and COPD-related symptoms, and the total number of participants included was substantial.

The limitation of this study was that most of the data were gathered through a questionnaire and therefore might be subject to recall bias and not as reliable as data taken only from medical records. The questions regarding swallowing and weight are indeed some of the ones most commonly used worldwide when evaluating a patient with oropharyngeal dysphagia, but our study would have benefited from an accompanying instrumental swallowing examination.

Conclusion {#s4b}
----------

We conclude that subjective swallowing symptoms are a common problem in patients with COPD and they are more prevalent in symptomatic patients and patients with lower physical capacity. Early detection of swallowing difficulties is important because they can significantly impact a person\'s quality of life. A high score on the mMRC or CAT and a classification in GOLD groups B and D may be predictive of a swallowing dysfunction and should be addressed by the COPD nurse or physician.

Future research is needed to study the prevalence of oropharyngeal dysphagia in patients with COPD and the relation to A--D grading (disease severity), physical capacity and dyspnoea. These investigations will lead to a better understanding of the risk factors of developing oropharyngeal dysphagia in patients with COPD and how to identify them in clinical practice.
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